Answers are grounded in this paper and cite their sources.
Translational study demonstrates actionable functional resolution of splicing variants in suspected monogenic neurometabolic disease, highlighting a scalable diagnostic RNA workflow.
Background Molecular diagnosis of rare disease plateaus at ~ 50%, partly due to technical limitations of short-read sequencing and the persistent challenge of interpreting variants of uncertain significance. Splice-altering variation represents a major source of unresolved cases, yet functional assessment remains difficult in routine practice. Methods We developed a fully modular, sample-to-answer workflow for targeted long-read RNA sequencing using Oxford Nanopore Technologies and applied it to six unsolved cases with suspected monogenic neurometabolic disease. Candidates were selected after WES/WGS and multidisciplinary team review indicating ≤ 5 genes of interest. The workflow was designed to be diagnostically deployable, enabling near-full-length transcript assessment from accessible tissues without reliance on large control cohorts. Results Targeted long-read RNA sequencing yielded actionable findings for all six probands. We confirmed pathogenic splice disruption in two cases, prompted gene exclusion in one case, and generated RNA-level evidence prioritising further DNA investigation in three cases. Across these scenarios, long-read RNA sequencing provided direct, mechanism-level insight that either resolved diagnosis or refined variant interpretation. The workflow provided near-full-length isoform structures with reproducible single-sample interpretation and produced informative results within a clinically relevant timeframe using standard long-read sequencing infrastructure. Conclusions Targeted long-read RNA sequencing offers rapid, cost-effective functional evidence to resolve variants of uncertain significance, direct DNA follow-up, and support timely diagnosis in rare disease. The RAPID workflow demonstrates that long-read RNA sequencing can be implemented within existing diagnostic infrastructure and provides a scalable route to routine transcript-level assessment in clinical genomics.
No takes yet. Share an insight, caveat, or question.
Montgomery et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: